PDSB
HEALTHCAREPDS Biotechnology Corporation
$1.06+0.00 (+0.00%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving PDSB Today?
No stock-specific AI insight has been generated for PDSB yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.51$1.92
$1.06
Fundamentals
Market Cap$59M
P/E Ratio—
EPS$-0.74
Dividend Yield—
Dividend / Share—
ROE-2.4%
Profit Margin—
Debt / Equity—
Trading
Volume430K
Avg Volume (10D)—
Shares Outstanding55.8M
PDSB News
20 articles- PDS Biotech Announces Conference Call and Webcast for 2026 First Quarter Financial ResultsYahoo Finance·May 6, 2026
- PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) TrialYahoo Finance·Apr 15, 2026
- PDS Biotechnology Corporation Q4 2025 Earnings Call SummaryMoby·Mar 31, 2026
- PDS Biotechnology Corp (PDSB) Q4 2025 Earnings Call Highlights: Financial Discipline Amid ...Yahoo Finance·Mar 31, 2026
- PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical AdvancementYahoo Finance·Mar 30, 2026
- PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial ResultsYahoo Finance·Mar 24, 2026
- PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated ApprovalYahoo Finance·Feb 20, 2026
- PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCIYahoo Finance·Jan 28, 2026
- PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101Yahoo Finance·Jan 22, 2026
- PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary EndpointYahoo Finance·Jan 9, 2026
- PDS Biotech Announces New Composition of Matter Patent for PDS0101 in JapanYahoo Finance·Dec 9, 2025
- PDS Biotechnology (PDSB) Upgraded to Buy: Here's WhyYahoo Finance·Dec 8, 2025
- PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)Yahoo Finance·Dec 2, 2025
- PDS Biotechnology price target lowered to $3 from $5 at B. RileyYahoo Finance·Nov 26, 2025
- PDS Biotechnology Corp (PDSB) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ...Yahoo Finance·Nov 13, 2025
- PDS Biotechnology: Q3 Earnings SnapshotYahoo Finance·Nov 13, 2025
- PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs UpdateYahoo Finance·Nov 13, 2025
- PDS Biotechnology Announces up to $11.1 Million Registered Direct OfferingYahoo Finance·Nov 11, 2025
- PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025Yahoo Finance·Nov 10, 2025
- PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial ResultsYahoo Finance·Nov 6, 2025
All 20 articles loaded
Price Data
Open$1.08
Previous Close$1.06
Day High$1.11
Day Low$1.04
52 Week High$1.92
52 Week Low$0.51
52-Week Range
$0.51$1.92
$1.06
Fundamentals
Market Cap$59M
P/E Ratio—
EPS$-0.74
Dividend Yield—
Dividend / Share—
ROE-2.4%
Profit Margin—
Debt / Equity—
Trading
Volume430K
Avg Volume (10D)—
Shares Outstanding55.8M
About PDS Biotechnology Corporation
PDS Biotechnology Corporation, a clinical-phase biopharmaceutical company, is focused on developing multifunctional cancer immunotherapies. The company is headquartered in Florham Park, New Jersey.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—